IMPORTANCE: Daily bathing of critically ill patients with the broad-spectrum, topical antimicrobial agent chlorhexidine is widely performed and may reduce health care-associated infections. OBJECTIVE: To determine if daily bathing of critically ill patients withchlorhexidine decreases the incidence of health care-associated infections. DESIGN, SETTING, AND PARTICIPANTS: A pragmatic cluster randomized, crossover study of 9340 patients admitted to 5 adult intensive care units of a tertiary medical center in Nashville, Tennessee, from July 2012 through July 2013. INTERVENTIONS: Units performed once-daily bathing of all patients with disposable cloths impregnated with 2% chlorhexidine or nonantimicrobial cloths as a control. Bathing treatments were performed for a 10-week period followed by a 2-week washout period during which patients were bathed with nonantimicrobial disposable cloths, before crossover to the alternate bathing treatment for 10 weeks. Each unit crossed over between bathing assignments 3 times during the study. MAIN OUTCOMES AND MEASURES: The primary prespecified outcome was a composite of central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated pneumonia (VAP), and Clostridium difficile infections. Secondary outcomes included rates of clinical cultures that tested positive for multidrug-resistant organisms, blood culture contamination, health care-associated bloodstream infections, and rates of the primary outcome by ICU. RESULTS: During the chlorhexidine bathing period, 55 infections occurred: 4 CLABSI, 21 CAUTI, 17 VAP, and 13 C difficile. During the control bathing period, 60 infections occurred: 4 CLABSI, 32 CAUTI, 8 VAP, and 16 C difficile. The primary outcome rate was 2.86 per 1000 patient-days during the chlorhexidine and 2.90 per 1000 patient-days during the control bathing periods (rate difference, -0.04; 95% CI, -1.10 to 1.01; P = .95). After adjusting for baseline variables, no difference between groups in the rate of the primary outcome was detected. Chlorhexidine bathing did not change rates of infection-related secondary outcomes including hospital-acquired bloodstream infections, blood culture contamination, or clinical cultures yielding multidrug-resistant organisms. In a prespecified subgroup analysis, no difference in the primary outcome was detected in any individual intensive care unit. CONCLUSION AND RELEVANCE: In this pragmatic trial, daily bathing with chlorhexidine did not reduce the incidence of health care-associated infections including CLABSIs, CAUTIs, VAP, or C difficile. These findings do not support daily bathing of critically ill patients withchlorhexidine. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02033187.
RCT Entities:
IMPORTANCE: Daily bathing of critically illpatients with the broad-spectrum, topical antimicrobial agent chlorhexidine is widely performed and may reduce health care-associated infections. OBJECTIVE: To determine if daily bathing of critically illpatients with chlorhexidine decreases the incidence of health care-associated infections. DESIGN, SETTING, AND PARTICIPANTS: A pragmatic cluster randomized, crossover study of 9340 patients admitted to 5 adult intensive care units of a tertiary medical center in Nashville, Tennessee, from July 2012 through July 2013. INTERVENTIONS: Units performed once-daily bathing of all patients with disposable cloths impregnated with 2% chlorhexidine or nonantimicrobial cloths as a control. Bathing treatments were performed for a 10-week period followed by a 2-week washout period during which patients were bathed with nonantimicrobial disposable cloths, before crossover to the alternate bathing treatment for 10 weeks. Each unit crossed over between bathing assignments 3 times during the study. MAIN OUTCOMES AND MEASURES: The primary prespecified outcome was a composite of central line-associated bloodstream infections (CLABSIs), catheter-associated urinary tract infections (CAUTIs), ventilator-associated pneumonia (VAP), and Clostridium difficile infections. Secondary outcomes included rates of clinical cultures that tested positive for multidrug-resistant organisms, blood culture contamination, health care-associated bloodstream infections, and rates of the primary outcome by ICU. RESULTS: During the chlorhexidine bathing period, 55 infections occurred: 4 CLABSI, 21 CAUTI, 17 VAP, and 13 C difficile. During the control bathing period, 60 infections occurred: 4 CLABSI, 32 CAUTI, 8 VAP, and 16 C difficile. The primary outcome rate was 2.86 per 1000 patient-days during the chlorhexidine and 2.90 per 1000 patient-days during the control bathing periods (rate difference, -0.04; 95% CI, -1.10 to 1.01; P = .95). After adjusting for baseline variables, no difference between groups in the rate of the primary outcome was detected. Chlorhexidine bathing did not change rates of infection-related secondary outcomes including hospital-acquired bloodstream infections, blood culture contamination, or clinical cultures yielding multidrug-resistant organisms. In a prespecified subgroup analysis, no difference in the primary outcome was detected in any individual intensive care unit. CONCLUSION AND RELEVANCE: In this pragmatic trial, daily bathing with chlorhexidine did not reduce the incidence of health care-associated infections including CLABSIs, CAUTIs, VAP, or C difficile. These findings do not support daily bathing of critically illpatients with chlorhexidine. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02033187.
Authors: Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint Journal: Clin Infect Dis Date: 2011-04-01 Impact factor: 9.079
Authors: David P Calfee; Cassandra D Salgado; Aaron M Milstone; Anthony D Harris; David T Kuhar; Julia Moody; Kathy Aureden; Susan S Huang; Lisa L Maragakis; Deborah S Yokoe Journal: Infect Control Hosp Epidemiol Date: 2014-07 Impact factor: 3.254
Authors: Nuntra Suwantarat; Karen C Carroll; Tsigereda Tekle; Tracy Ross; Lisa L Maragakis; Sara E Cosgrove; Aaron M Milstone Journal: Infect Control Hosp Epidemiol Date: 2014-07-23 Impact factor: 3.254
Authors: Steven Z Kassakian; Leonard A Mermel; Julie A Jefferson; Stephen L Parenteau; Jason T Machan Journal: Infect Control Hosp Epidemiol Date: 2011-03 Impact factor: 3.254
Authors: Michael W Climo; Deborah S Yokoe; David K Warren; Trish M Perl; Maureen Bolon; Loreen A Herwaldt; Robert A Weinstein; Kent A Sepkowitz; John A Jernigan; Kakotan Sanogo; Edward S Wong Journal: N Engl J Med Date: 2013-02-07 Impact factor: 91.245
Authors: Melissa A Viray; James C Morley; Craig M Coopersmith; Marin H Kollef; Victoria J Fraser; David K Warren Journal: Infect Control Hosp Epidemiol Date: 2014-01-24 Impact factor: 3.254
Authors: Mark E Rupp; R Jennifer Cavalieri; Elizabeth Lyden; Jennifer Kucera; MaryAnn Martin; Teresa Fitzgerald; Kate Tyner; James R Anderson; Trevor C VanSchooneveld Journal: Infect Control Hosp Epidemiol Date: 2012-09-21 Impact factor: 3.254
Authors: Susan S Huang; Edward Septimus; Ken Kleinman; Julia Moody; Jason Hickok; Taliser R Avery; Julie Lankiewicz; Adrijana Gombosev; Leah Terpstra; Fallon Hartford; Mary K Hayden; John A Jernigan; Robert A Weinstein; Victoria J Fraser; Katherine Haffenreffer; Eric Cui; Rebecca E Kaganov; Karen Lolans; Jonathan B Perlin; Richard Platt Journal: N Engl J Med Date: 2013-05-29 Impact factor: 91.245